EGFR and non-small cell lung carcinoma: For first-generation EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, their mechanism of action depends on the reversible competitive binding to the ATP binding site of EGFR, and they revolutionized the treatment of NSCLC patients with mutations at L858R and Del19.